[Targeted therapies and high blood pressure]

"Targeted therapies and hypertension The recent advent of molecular targeted agents represents an important improvement in the management of cancer patients. The administration of therapies targeting the vascular endothelial growth factor or its receptor could be associated with side effects including cardiovascular complications (hypertension, heart Failure, QT interval prolongation). Hypertension due to molecular targeted agents is considered as a class effect, which can affect nearly 90% of treated patients; its management is most often based on the introduction of anti-hypertensive treatment and more rarely on dose drug reduction."